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Background: Breast cancer surgery in older women is variable and sometimes non-standard owing to
concerns about morbidity. Bridging the Age Gap in Breast Cancer is a prospective multicentre cohort
study aiming to determine factors influencing treatment selection and outcomes from surgery for older
patients with breast cancer.
Methods: Women aged at least 70 years with operable breast cancer were recruited from 57 UK breast
units between 2013 and 2018. Associations between patient and tumour characteristics and type of surgery
in the breast and axilla were evaluated using univariable andmultivariable analyses. Oncological outcomes,
adverse events and quality-of-life (QoL) outcomes were monitored for 2 years.
Results: Among 3375 women recruited, surgery was performed in 2816 patients, of whom 24 with
inadequate data were excluded. Sixty-two women had bilateral tumours, giving a total of 2854 surgi-
cal events. Median age was 76 (range 70–95) years. Breast surgery comprised mastectomy in 1138 and
breast-conserving surgery in 1716 procedures. Axillary surgery comprised axillary lymph node dissec-
tion in 575 and sentinel node biopsy in 2203; 76 had no axillary surgery. Age, frailty, dementia and
co-morbidities were predictors of mastectomy (multivariable odds ratio (OR) for age 1⋅06, 95 per cent
c.i. 1⋅05 to 1⋅08). Age, frailty and co-morbidity were significant predictors of no axillary surgery (OR for
age 0⋅91, 0⋅87 to 0⋅96). The rate of adverse events was moderate (551 of 2854, 19⋅3 per cent), with no
30-day mortality. Long-term QoL and functional independence were adversely affected by surgery.
Conclusion: Breast cancer surgery is safe in women aged 70 years or more, with serious adverse events
being rare and no mortality. Age, ill health and frailty all influence surgical decision-making. Surgery has
a negative impact on QoL and independence, which must be considered when counselling patients about
choices.
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Introduction
The age of the population in the UK is rising, and average
life expectancy among women has risen from 80⋅5 years in
2003 to 82⋅9 years in 20161. In 2015, 54 741 women were
diagnosed with breast cancer, of whom over one-third were
aged over 70 years2. Although overall survival outcomes are
predictably inferior in older than younger women owing to
competing causes of death, breast cancer-specific survival
(BCSS) rates are also lower3. This deficit is due to stage
variation, compounded by treatment variance because of
concerns about the morbidity of certain therapies.
Older women present with more advanced disease4,
larger median tumour size5–7, higher rates of node
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positivity, and higher rates of locally advanced8 and
metastatic9 disease. This is likely to have an adverse impact
on BCSS, and is largely the result of lack of routine
screening in this age group combined with reduced breast
awareness10.
The UK National Audit of Breast Cancer in Older
Patients (NABCOP) has shown significant variation in
rates of surgery in older women between centres in the
UK11. Similar variation in surgery rates has been noted
between European countries, with a recent audit12 showing
low rates in the UK compared with Poland, the Nether-
lands, Belgium and Ireland. Rates of surgery are also much
higher in the USA13.
For the frailest older patients, surgery may have mini-
mal benefit in terms of BCSS and cause harm, as reported
in frail nursing home residents14. Surgery for breast can-
cer is, however, low risk and safe for the majority of
older women. Previous published series9,15 have shown that
modern breast cancer surgery and anaesthesia has a very
low mortality rate; only 0⋅2 per cent died during admis-
sion. Morbidity should not be underestimated, with risk
of seroma, wound complications and, in the longer term,
arm morbidity such as lymphoedema and impairment of
shoulder movement following axillary surgery. In addi-
tion, there may be a long-term and permanent adverse
impact on quality of life (QoL) and a loss of functional
reserve in this age group. These factors have received lim-
ited attention, butmay be of significant importance to older
women16,17.
The National Institute for Health and Care Excellence
(NICE) guidance18 for the management of early breast
cancer published in 2009 recommends that the primary
breast cancer should be removed and appropriate axillary
management provided for all patients with breast cancer.
Surgical management options for the breast are either mas-
tectomy or breast-conserving surgery (BCS), and those
for the axilla are sentinel lymph node biopsy (SLNB) and
axillary lymph node dissection (ALND) or axillary radio-
therapy for patients with axillary nodal metastases. The
guidance does not make age-specific recommendations for
treatment. Treatment algorithms have become more com-
plex in recent years for the management of the axilla, per-
mitting some flexibility in low-risk axillary disease to avoid
ALND, following publication of the Z119 and AMAROS20
trials. The UK has, however, been slow to adopt these pro-
tocols, with NICE guidelines only recently being revised
in light of these new data21. During the present trial inter-
val, NICE guideline concordant care mandated ALND for
all women with macrometastatic axillary disease and SLNB
for all N0 disease, with no age or fitness stratification unless
the woman was clearly unfit for anaesthesia.
The Bridging the Age Gap in Breast Cancer study22 is
a National Institute for Health Research (NIHR)-funded
programme (ISRCTN46099296) examining various
aspects of the management of older patients with breast
cancer. This study focused on surgical outcomes in the
larger Age Gap study, and aimed to examine the charac-
teristics and outcomes (survival, QoL and adverse events)
of women aged at least 70 years in the UK undergoing
surgery for breast cancer.
Methods
This was a prospective, multicentre observational cohort
study. Patients could participate at three levels: full par-
ticipation, partial (no requirement to complete QoL
assessments) or proxy (simple third-party data collection
for women with cognitive impairment). Patients were
recruited from 57 UK breast units in England and Wales
(Appendix S1, supporting information).
Ethics approval and research governance approval was
obtained (IRAS: 12 LO 1808). All patients gave written
informed consent, or consent was given by a proxy if the
patient was cognitively impaired.
Inclusion and exclusion criteria
The study includedwomen aged at least 70 years at the time
of breast cancer diagnosis with primary operable invasive
breast cancer (T1–4N0–2M0). Those with multifocal
and bilateral cancers were eligible. Exclusion criteria were:
disease unsuitable for surgery and previous breast cancer
within 5 years. Patients without cognitive capacity were
eligible if a relative or friend was willing to sign proxy
consent.
Baseline data collection
A baseline comprehensive geriatric assessment was carried
out using a range of validated tools, with data collected
on: age; co-morbidities assessed using the Charlson
Co-morbidity Index (CCI) score23; frailty, evaluated by
activities of daily living (ADL)24 and instrumental activi-
ties of daily living (IADL)25; cognitive function, assessed
using the Mini Mental State Examination (MMSE)26, with
cognitive impairment defined as a MMSE score below
27, proxy consent or identification of dementia on the
CCI; and nutritional status, evaluated using the abridged
patient-generated subjective global assessment27. Baseline
tumour characteristics, including tumour size, biological
subtype, grade and nodal status (both clinical, imaging and
pathological status) were registered.
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Breast surgery was categorized based on the maximum
procedure the patient underwent as: BCS, which included
wide local excision with or without wire guidance, thera-
peutic mammoplasty and segmentectomy; or mastectomy,
with or without reconstruction. As an example, a patient
who initially had BCS followed by mastectomy because of
involved margins was included in the mastectomy group
as the patient was clearly deemed fit enough for the proce-
dure and because the final surgery affects the risk of adverse
events. Axillary surgery was classified as no axillary surgery,
SLNB (axillary sampling, internal mammary node biopsy)
or ALND.
Surgery was grouped into major (mastectomy and/or
ALND) and minor (BCS with or without SLNB). For
patients who had a bilateral procedure for invasive breast
cancer, this was assessed as two unilateral procedures.
Outcomes
Mortality related to surgery was defined as death within
30 days of surgery or surgery being documented as con-
tributing to cause of death. Death from breast cancer was
assessed by death certification and expert review of all
causes of death. Causes of death were grouped into breast
cancer-related or other causes.
Complications, obtained by follow-up to 2 years, were
categorized using the Common Terminology Criteria
for Adverse Events (CTCAE)28, and grouped into sys-
temic (atelectasis, stroke, infarction, deep vein thrombosis
(DVT)/embolism, arrhythmia, allergic reaction and
somnolence) and local (lymphoedema, neuropathy, func-
tional difference, wound pain, wound, necrosis, infection,
haematoma, seroma and haemorrhage). Seroma was
excluded from some analyses.
QoL data were compared at baseline (before starting
treatment), 6weeks and 6months, and then at 6-month
intervals up to 2 years after treatment using validated tools:
the European Organisation for Research and Treatment
of Cancer (EORTC) QLQ-C30 (generic)29, QLQ-BR23
(breast cancer-related)30 and ELD14 (elderly-specific)31,
and the EuroQol Five Dimensions (EQ-5D™; EuroQol
Group, Rotterdam, the Netherlands). QoL was assessed
only in patients who consented to full participation.
Statistical analysis
This article reports a planned subanalysis of the larger Age
Gap study; because surgical outcomes were not the primary
outcome measures, the sample size was not calculated to
serve this analysis.
The significance of type of breast surgery and axil-
lary surgery in relation to co-morbidity, dementia, IADL,
ADL and complications was analysed using χ2 and Fisher’s
exact test.
Multivariable analyses were performed in the statistical
package R 3.4.1 (R Foundation for Statistical Computing,
Vienna, Austria). A binary logistic regression model was
developed to predict the odds of a patient receiving a mas-
tectomy, whereas multinomial logistic regression was used
to predict the odds of a woman receiving SLNB versus no
axillary surgery or ALND versus no axillary surgery. In both
analyses, univariable models were first built using the fol-
lowing variables: age, tumour size, preoperative nodal sta-
tus, tumour grade, CCI score, MMSE, ADL, IADL and
BMI. Themodel Akaike information criterion (AIC) values
were used to determine which variables had most predic-
tive importance. Multivariable models were then built by
adding variables in order of importance until the model
AIC value ceased to improve. Further tests with addition
and removal of individual co-variables and comparison of
AIC led to a preferred model, which explained but did not
overfit the data. To account formissing data (approximately
15 per cent of total relevant fields), 25 complete data sets
were formed using multiple imputation. Separate models,
using the identified co-variables, were estimated using each
of these complete data sets and the results combined to pro-
duce the final models. The R packagemice 3.4.032 was used
for multiple imputation and the statistical package nnet
7.3.1233 for logistic regression modelling.
For the QoL analysis, where relevant, the scores were
converted to a 0–100 scale, as described in the EORTC
scoring manual34, and mean values compared using the
independent t test.
P< 0⋅050 was considered significant and SPSS® version
25 (IBM, Armonk, New York, USA) was used for statistical
analysis, unless indicated otherwise.
Results
A total of 3375 women with primary operable breast can-
cer were recruited to the parent Bridging the Age Gap
study between February 2013 and June 2018. Of these,
2816 (83⋅4 per cent) had surgical treatment, and these are
the focus of the present article. The population recruited
and procedures undertaken in the surgical population are
shown in Fig. 1. The median age of surgical patients was 76
(range 70–95) years. Baseline patient and tumour charac-
teristics are shown in Tables 1 and 2 respectively.
Adequate data for analysis were available for 2792 of 2816
surgically treated patients. Most of the initial 3375 patients
who did not have surgery received primary endocrine
therapy (Fig. 1). Sixty-two bilateral tumours had operative
treatment, giving a total of 2854 surgical events for analysis.
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Fig. 1 Study flow chart
Cohort consented
n=3460
Eligible patients
n=3375
Excluded owing to metastatic disease,
withdrawal of consent or for other reason n=85
Excluded n=559
 Primary endocrine therapy n=505
 Other non-surgical treatments
 (either no treatment or palliative RT) n=54
Patients having surgery
n=2816
Patients having surgery n=2792
 Unilateral n=2730
 Bilateral n=62
Breasts operated n=2854
Initial mastectomy
n=1083 breasts
Initial BCS n=1771 breasts
 Positive margin n=463
Positive margins
n=55
BCS group
n=1716
Initial SLNB n=1541
 N0 n=1281
 N1 n=259
 Missing n=1
Initial ALND
 n=129
ALND group
 n=183*
Initial ALND
 n=329
ALND group
 n=392
SLNB group n=1487
 N0 n=1281
 N1 n=205
 Missing n=1
Mastectomy group
 n=1138*
Initial SLNB n=779
 N0 n=565
 N1 n=213
 Missing n=1
SLNB group n=716
 N0 n=565
 N1 n=150
 Missing n=1
No axillary surgery group
 n=46
No axillary surgery group
 n=30
No further axillary surgery
 n=2203
Excluded owing to inadequate surgical data n=24
N1 n=54N1 n=63
*Classed as major surgery. RT, radiotherapy; BCS, breast-conserving surgery; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy.
Among the surgical patients, 2445 of 2792 (87⋅6 per cent)
had oestrogen receptor-positive tumours, of whom 2331
(95⋅3 per cent) received adjuvant endocrine therapy. Some
343 patients were recorded as having human epidermal
growth factor receptor 2-positive disease and 168 (49⋅0
per cent) of these received adjuvant trastuzumab. In all,
1756 of 2792 patients received adjuvant radiotherapy
(62⋅9 per cent) and 134 (4⋅8 per cent) had adjuvant
chemotherapy.
BCS was undertaken as the initial surgery in 1771 breast
procedures, with therapeutic mammoplasty in 67 (3⋅8 per
cent). Tumour margins were positive in 463 of these pro-
cedures; however, further surgery was undertaken in only
134 (28⋅9 per cent), with one or more re-excisions in 79
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 1 Baseline patient characteristics of surgical population
Breast surgery type Axillary surgery type
BCS
(n = 1716)
Mastectomy
(n = 1138) P*
SLNB
(n = 2203)
ALND
(n = 575)
No axillary
surgery
(n = 76) P*
Age (years) < 0⋅001 <0⋅001
70–74 828 (70⋅1) 353 (29⋅9) 968 (82⋅0) 196 (16⋅6) 17 (1⋅4)
75–79 541 (59⋅1) 374 (40⋅9) 706 (77⋅2) 195 (21⋅3) 14 (1⋅5)
80–84 252 (47⋅9) 274 (52⋅1) 372 (70⋅7) 129 (24⋅5) 25 (4⋅8)
≥85 95 (40⋅9) 137 (59⋅1) 157 (67⋅7) 55 (23⋅7) 20 (8⋅6)
CCI score <0⋅001 <0⋅001
3 681 (65⋅6) 357 (34⋅4) 837 (80⋅6) 191 (18⋅4) 10 (1⋅0)
4 361 (55⋅4) 291 (44⋅6) 505 (77⋅5) 138 (21⋅2) 9 (1⋅4)
5 337 (59⋅5) 229 (40⋅5) 438 (77⋅4) 111 (19⋅6) 17 (3⋅0)
>5 273 (55⋅3) 221 (44⋅7) 347 (70⋅2) 110 (22⋅3) 37 (7⋅5)
Missing 64 (61⋅5) 40 (38⋅5) 76 (73⋅1) 25 (24⋅0) 3 (2⋅9)
Dementia 0⋅025 0⋅314
Normal (MMSE ≥27) 1050 (62⋅4) 633 (37⋅6) 1306 (77⋅6) 331 (19⋅7) 46 (2⋅7)
Impaired (MMSE <27, consultee
participant, known dementia)
159 (55⋅4) 128 (44⋅6) 212 (73⋅9) 64 (22⋅3) 11 (3⋅8)
Missing 507 (57⋅4) 377 (42⋅6) 685 (77⋅4) 180 (20⋅4) 19 (2⋅1)
ADL 0⋅032 0⋅103
Independent 1218 (61⋅2) 772 (38⋅8) 1559 (78⋅3) 384 (19⋅3) 47 (2⋅4)
Dependent in ≥1 332 (56⋅3) 258 (43⋅7) 441 (74⋅7) 128 (21⋅7) 21 (3⋅6)
Missing 166 (60⋅6) 108 (39⋅4) 203 (74⋅1) 63 (23⋅0) 8 (2⋅9)
IADL <0⋅001 <0⋅001
Independent 1258 (61⋅8) 776 (38⋅2) 1615 (79⋅4) 380 (18⋅7) 39 (1⋅9)
Dependent in ≥1 270 (52⋅7) 242 (47⋅3) 357 (69⋅7) 121 (23⋅6) 34 (6⋅6)
Missing 188 (61⋅0) 120 (39⋅0) 231 (75⋅0) 74 (24⋅0) 3 (1⋅0)
BMI (kg/m2) 0⋅354 0⋅001
<18⋅5 12 (52) 11 (48) 15 (65) 6 (26) 2 (9)
18⋅5–24⋅9 441 (57⋅7) 323 (42⋅3) 590 (77⋅2) 146 (19⋅1) 28 (3⋅7)
25⋅0–29⋅9 570 (62⋅3) 345 (37⋅7) 732 (80⋅0) 165 (18⋅0) 18 (2⋅0)
30⋅0–34⋅9 276 (61⋅6) 172 (38⋅4) 344 (76⋅8) 94 (21⋅0) 10 (2⋅2)
35⋅0–39⋅9 111 (59⋅0) 77 (41⋅0) 137 (72⋅9) 44 (23⋅4) 7 (3⋅7)
>40⋅0 47 (64) 27 (36) 48 (65) 26 (35) 0 (0)
Missing 259 (58⋅6) 183 (41⋅4) 337 (76⋅2) 94 (21⋅3) 11 (2⋅5)
Values in parentheses are percentages. BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; CCI,
Charlson Co-morbidity Index; MMSE, Mini Mental State Examination; ADL, activities of daily living; IADL, instrumental activities of daily living.
*χ2 test for trend.
and ultimately completion mastectomy in 55. Of the 463
procedures resulting in positive margins, the surgical mar-
gin was recorded as 0mm in 143 (30⋅9 per cent), 1mm in
259 (55⋅9 per cent), and more than 1mm or no distance
recorded in the remaining 61 (13⋅2 per cent). BCS was the
main procedure in 1716 breasts, with adjuvant radiotherapy
administered to 1432 (80⋅9 per cent).
Of 2854 breast operations, 1138 (39⋅9 per cent) were
mastectomies, with reconstruction in 32 (2⋅8 per cent).
Adjuvant therapy was administered after 363 of 1138 (31⋅9
per cent).Median tumour size was larger in themastectomy
group (30 versus 18mm; P< 0⋅001).
In terms of axillary surgery, ALND was undertaken in
575 of 2854 axillary procedures (20⋅1 per cent), SLNB
in 2203 (77⋅2 per cent) and no axillary surgery was per-
formed in 76 (2⋅7 per cent). In the ALND group, pos-
itive lymph nodes were documented 560 of 575 (97⋅4
per cent) or the patient proceeded straight to ALND
owing to clinically positive nodes; a positive SLNB was
followed by ALND in 117 cases. Of 2320 SLNBs doc-
umented as the first axillary procedure, positive lymph
nodes were recorded in 472 (20⋅3 per cent) and no lymph
node involvement in 1846 (79⋅4 per cent); data were miss-
ing for the remaining two procedures. Completion ALND
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Table 2 Baseline tumour characteristics of surgical population
Breast surgery type Axillary surgery type
BCS
(n = 1716)
Mastectomy
(n = 1138)
SLNB
(n = 2203)
ALND
(n = 575)
No axillary
surgery (n = 76)
Total
(n = 2855)
Tumour size (mm)*
0–9 214 56 241 18 11 270
10–19 709 217 807 103 16 926
20–29 526 293 631 159 29 819
30–39 163 230 263 123 7 393
≥40 88 335 242 168 13 423
Missing 16 7 19 4 0 23
Median (range) 18 (0–100) 29 (0–210) 20 (0–155) 30 (0–210) 22 (0–120)
Tumour grade
1 312 81 359 26 8 393
2 952 595 1246 263 38 1547
3 431 441 569 279 24 872
Missing 21 21 29 7 6 42
Oestrogen receptor status
Positive 1535 910 1924 460 61 2445
Negative 167 210 254 110 13 377
Missing 14 18 25 5 2 32
HER2 status
Positive 149 194 225 111 7 343
Negative 1470 892 1870 433 59 2362
Missing 97 52 108 31 10 149
Focality
Unifocal 1520 834 1849 442 63 2354
Multifocal 58 207 179 79 7 265
Missing 138 97 175 54 6 235
Axillary node stage
N0 1331 594 1846 14 65 1925
≥ N1 383 536 355 560 4 919
Missing 2 8 2 1 7 10
BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; HER2, human epidermal growth factor
receptor 2. *P< 0⋅001, BCS versus mastectomy (χ2 test).
was undertaken after only 117 of 472 positive SLNBs
(24⋅8 per cent). Postoperative radiotherapy was adminis-
tered after 257 of the remaining 355 (72⋅4 per cent). Thus,
SLNB was the only axillary procedure for 2203 breast
cancers.
Impact of age, co-morbidity, frailty and dementia
on type of surgery
Univariable analysis was initially performed to identify
associations between type of surgery and patient factors.
Age was a significant predictor of mastectomy, with the
youngest age group having a rate of only 29⋅9 per cent
comparedwith 59⋅1 per cent in the oldest group (P< 0⋅001)
(Table 1). Age was also a significant predictor of having no
axillary surgery, with a rate of 1⋅4 per cent in the youngest
age group compared with 8⋅6 per cent in the oldest group
(P< 0⋅001).
Increasing co-morbidity scores were associated with
increasing mastectomy rates; the rate was 34⋅4 per cent in
the group a CCI score of 3, compared with 44⋅7 per cent
in the group with a CCI of above 5 (P< 0⋅001). Rates of no
axillary surgery rose steadily as the co-morbidity burden
increased (1⋅0 per cent for CCI score 3 versus 7⋅5 per cent
for score above 5; P< 0⋅001).
Impaired cognitive function was associated with higher
rates of mastectomy (37⋅6 versus 44⋅6 per cent in groups
with normal versus impaired cognitive function;P = 0⋅025).
There was a slightly higher rate of no axillary surgery in
the dementia group, but this was not statistically significant
(2⋅9 per cent versus 3⋅8 per cent in those with impaired
cognitive function; P = 0⋅314).
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Frailty, as measured by the ADL, showed an association
with mastectomy; the rate was 38⋅8 per cent in the group
of patients who were independent in all ADLs compared
with 43⋅7 per cent when the patients were dependent in
one or more ADL domain (P = 0⋅032). Moreover, a higher
rate of no axillary surgery was observed in the frailer
group, although this did not reach statistical significance
(2⋅4 versus 3⋅6 per cent; P = 0⋅103). For IADL, there was
an association between frailty and mastectomy rate (38⋅2
versus 47⋅3 per cent in groups that were independent versus
not independent in all domains of IADL; P< 0⋅001). The
group that was independent in all domains of IADL also
had a lower rate of no axillary surgery (1⋅9 versus 6⋅6 per
cent; P< 0⋅001).
In multivariable analysis, co-variables identified for the
mastectomy model were age, preoperative tumour size and
preoperative nodal status. Tumour size was the strongest
predictor of whether a patient underwent mastectomy or
BCS. Age was also a significant independent predictor, as
was preoperative nodal status, which may reflect the close
association between tumour size and nodal status (Table 3).
Co-variables identified for the axillary surgery model were
age, preoperative tumour size, preoperative nodal status,
CCI score, IADL and BMI. Preoperative nodal status
and tumour size were significant predictive factors for
undergoing ALND. Increasing age, co-morbidity burden
and frailty (as determined by IADL) were all associated
with higher rates of no axillary surgery (Table 3).
Complications and mortality
Surgical complications were classified by type and severity
using the CTCAE system27, and further categorized as
systemic or local wound complications. For analysis of
complication rates, patients who underwent mastectomy
and/or ALND were classified as having major surgery
(1321 procedures); the remaining patients who had BCS
with either SLNB or no axillary surgery were classified as
having minor surgery (1533 procedures) (Fig. 1).
In total, 551 of 2854 operations (19⋅3 per cent) resulted
in complications; some patients had more than one adverse
event. The total number of complications, excluding
seromas, was 761 (Table S1, supporting information). The
overall rate of systemic complications, including cardiores-
piratory problems, stroke, DVT or pulmonary embolism,
was 59 of 2854 (2⋅1 per cent). As expected, major surgery
had significantly higher rates of complications than minor
surgery, but the rate was very low overall (2⋅9 versus 1⋅4 per
cent; 95 per cent c.i. for difference in rates 0⋅5 to 2⋅6 per
cent; P = 0⋅005). There was no clear association between
systemic complications and age, co-morbidity, frailty or
cognitive capacity.
Table 3 Multivariable analysis of type of surgery
Odds ratio P
Type of breast surgery (n = 2854)
(mastectomy versus BCS*)
Node-positive before surgery 2⋅30 (1⋅82, 2⋅91) < 0⋅001
Tumour size (mm) 1⋅07 (1⋅06, 1⋅09) < 0⋅001
Age (years) 1⋅06 (1⋅05, 1⋅08) < 0⋅001
Type of axillary surgery (n = 2854)
SLNB versus no surgery*
Node-positive before surgery 1⋅02 (0⋅35, 2⋅97) 0⋅970
Tumour size (mm) 1⋅02 (0⋅99, 1⋅04) 0⋅231
Age (years) 0⋅91 (0⋅87, 0⋅96) < 0⋅001
CCI score 0⋅72 (0⋅62, 0⋅84) < 0⋅001
IADL 1⋅26 (1⋅06, 1⋅49) 0⋅008
BMI (kg/m2) 1⋅02 (0⋅98, 1⋅06) 0⋅406
ALND versus no surgery*
Node-positive before surgery 23⋅05 (7⋅87, 67⋅56) < 0⋅001
Tumour size (mm) 1⋅05 (1⋅02, 1⋅08) < 0⋅001
Age (years) 0⋅92 (0⋅87, 0⋅97) < 0⋅001
CCI score 0⋅75 (0⋅63, 0⋅88) < 0⋅001
IADL 1⋅17 (0⋅96, 1⋅42) 0⋅127
BMI (kg/m2) 1⋅04 (1⋅00, 1⋅09) 0⋅062
Values in parentheses are 95 per cent confidence intervals. *Reference
group. BCS, breast-conserving surgery; SLNB, sentinel lymph node
biopsy; CCI, Charlson Co-morbidity Index; IADL, instrumental activities
of daily living; ALND, axillary lymph node dissection.
Local wound complications included haematoma, infec-
tion and wound dehiscence. Seroma was excluded from this
analysis as it is an expected consequence of breast surgery
and causes minimal harm (Table S1, supporting informa-
tion). The seroma rate in the present cohort was 25⋅4
per cent. In total 525 operations (18⋅4 per cent) resulted
in local wound complications. These were more common
withmajor thanminor surgery (22⋅7 versus 14⋅7 per cent; 95
per cent c.i. for difference 5⋅2 to 10⋅9 per cent; P< 0⋅001).
There was no correlation with age, co-morbidity or cogni-
tive status, but a positive association with frailty (ADL) on
univariable analysis (22⋅7 versus 17⋅7 per cent in frail versus
non-frail groups; 95 per cent c.i. for difference 1⋅4 to 8⋅6
per cent; P = 0⋅006). In terms of return to the operating
theatre for local complications, there were five haematoma
evacuations, one wound debridement and closure, and two
patients had drainage and excision of a chronic seroma
cavity.
There were no deaths reported within 30 days of surgery
or attributable to surgery in this large prospective series.
Influence of surgery on quality of life
Patients who had mastectomy had a significant drop in
scores on the global health status domains of theQLQ-C30
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Fig. 2 Change in mean quality-of-life scores over time by type of surgery
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questionnaire at 6weeks compared with those who had
BCS (mean 68⋅9 versus 71⋅44; 95 per cent c.i. for difference
0⋅74 to 4⋅32; P = 0⋅006), although there was no difference
by 6months (Fig. 2a). Scores on the functional domain of
the QLQ-ELD15 questionnaire decreased in both groups
after surgery, but patients who underwent mastectomy
had significantly lower scores and this difference persisted;
scores continued to deteriorate in both groups to the 2-year
mark (65⋅58 versus 71⋅13; 95 per cent c.i. for difference 2⋅34
to 8⋅75; P = 0⋅001) (Fig. 2b).
Women who had ALND showed a significant drop in
QLQ-C30 global health status scores at 6weeks compared
with those who had SLNB, and this difference persisted at
2 years after operation (66⋅43 versus 70⋅80; 95 per cent c.i.
for difference 1⋅38 to 7⋅36; P = 0⋅004) (Fig. 2d). Similarly,
there was a continual decline throughout the study interval
in scores on the functional domains of the QLQ-ELD15
questionnaire in both ALND and SLNB groups, although
scores were significantly lower after ALND (62⋅50 versus
71⋅10 at 2 years; 95 per cent c.i. for difference 4⋅72 to 12⋅48;
P< 0⋅001) (Fig. 2e).
Body image scores (QLQ-BR23 BRBI) were significantly
lower in the mastectomy group than the BCS group at
all time points, especially immediately after surgery (82⋅54
versus 92⋅15; 95 per cent c.i. for difference 7⋅90 to 11⋅32;
P< 0⋅001), although a difference was already present at
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baseline (91⋅8 versus 94⋅5; 95 per cent c.i. for difference 1⋅43
to 4⋅03; P< 0⋅001).
Patients who underwent mastectomy initially had signif-
icantly poorer QoL scores in the breast symptoms domain
of the QLQ-BR23 compared with those who had BCS
(23⋅52 versus 21⋅43 at 6weeks; 95 per cent c.i. for differ-
ence 0⋅32 to 3⋅85; P = 0⋅021) (Fig. 2c). However, this had
changed by 6months after treatment, with the BCS group
having worse scores (14⋅09 versus 15⋅61 for mastectomy
versus BCS; 95 per cent c.i. for difference in scores 0⋅01
to 3⋅05; P = 0⋅048). By 2 years, there was no difference in
scores (10⋅87 versus 9⋅86; 95 per cent c.i. for difference 0⋅62
to 2⋅63; P = 0⋅223). Patients who had ALND had signifi-
cantly poorer QoL scores in the arm symptoms domain of
theQLQ-BR23 than those who underwent SLNB, and this
difference persisted at 2 years (22⋅22 versus 12⋅71; 95 per
cent c.i. for difference 6⋅52 to 12⋅50; P< 0⋅001) (Fig. 2f ).
Discussion
In this large, prospective, multicentre cohort study of
women aged at least 70 years with operable breast cancer
treated between 2013 and 2018, 83⋅4 per cent had surgery
as primary treatment. Limitations of the study include its
non-randomized nature, meaning that there may be some
inherent bias. Additionally, there were issues with com-
pleteness of data, and data were imputed when deemed
appropriate31.
BCS was the most common operation (60⋅1 per cent).
The rate of mastectomy varied according to tumour size,
multifocality, and patient age and fitness. The overall
mastectomy rate (39⋅9 per cent) is similar to that reported
in the recent NABCOP audit11. After BCS procedures
with positive margins, further operation, as recommended
in UK guidelines18 extant at the time of the study, was not
undertaken in 71⋅1 per cent of breasts. However, it is worth
noting that global and European guidelines35,36 during
this interval accepted ‘no tumour at the inked margin’
rather than ‘margin more than 1mm’ as the definition
of a clear margin, and this may have begun to influence
practice in the UK. Similarly, contrary to recommended
practice during the study interval, ALND was not carried
out after 75⋅2 per cent of 472 positive SLNBs, although
no distinction was made between macrometastases and
micrometastases, which may explain why some patients did
not proceed to ALND. During the study period there was
a trend towards a de-escalation of axillary surgery after the
publication of, among others, the Z1119 and AMAROS20
trials, which demonstrated that omitting further axillary
surgery and/or axillary radiotherapy provides adequate
regional control in women with one to two positive
sentinel nodes; some 20 per cent had no axillary surgery
at all. For some of these patients, this reflects concerns
about frailty and co-morbidity, but there is also increasing
recognition that the axilla may be being overtreated in
clinically node-negative dieases37.
Reconstruction after mastectomy was rare, occurring
after only 2⋅8 per cent of procedures, which is much lower
than the national average of over 20 per cent for patients
of all ages. The rate of reconstruction is known to fall
after a threshold of approximately 70 years of age, and a
woman’s age has previously been shown to be the sin-
gle most important factor in predicting whether they are
offered reconstruction15. This may reflect the reluctance
of surgeons to undertake major surgery in the older popu-
lation with an increased rate of co-morbidities and frailty,
or a lack of willingness of patients to undergo this type
of procedure15. Similarly, the rate of therapeutic mammo-
plasty was low at only 3⋅8 per cent, likely reflecting the same
concerns about surgical morbidity, the risk of fat and nipple
necrosis in patients with predominantly fatty breasts, and a
higher risk of vascular insufficiency.
Analysis of treatment allocation showed that age was a
significant determinant of both types of breast and axillary
surgery, with rates of mastectomy doubling between the
youngest and oldest age groups. It is important to note
that some patients in the youngest age group will have
undergone breast screening mammography, so there may
have been a higher proportion of small, screen-detected
tumours in this group, but also older patients have been
shown to be less breast aware and thus present with larger
tumours5,10. Rates of ALND increased with age in line with
higher rates of nodal involvement in older cohorts8, and
rates of no axillary surgery increased sixfold between the
youngest and oldest groups, potentially reflecting a trend
towards less aggressive management in clinically negative
axillas in light of recent trials19, particularly where SLNB
is not expected to influence staging or further treatment
choices. Rates of mastectomy also rose with increasing
levels of co-morbidity, dementia and frailty in univariable
analysis, possibly reflecting a desire to avoid radiotherapy
in frailer, less fit women. Higher rates of omission of
axillary surgery were also seen in patients with increased
levels of co-morbidity and frailty, which again is likely to
reflect treatment decisions being related to the shorter life
expectancy in these patients.
The rate of systemic complications was low at 2⋅1 per
cent, and there were no surgery-related deaths in the
cohort, reaffirming that surgery for breast cancer in the
older population is safe. This study included a selected sub-
group of patients deemed suitable for surgery. Although
rates of local complications were higher at 18⋅4 per cent,
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only 0⋅3 per cent required a return to theatre. As expected,
rates of lymphoedema were higher in the major surgery
group and occurred more commonly after ALND than
SLNB38, although the rate in this series was very low over-
all (26 of 2854, 0⋅9 per cent). This may reflect the relatively
short follow-up of only 2 years, and that only symptomatic
lymphoedema as reported by the patients was captured,
indicating a degree of under-reporting. QoL scores in the
arm symptoms domain were significantly worse in patients
undergoing ALND compared with SLNB, suggesting that
even in the absence of overt lymphoedema, these patients
have symptoms following axillary clearance. This was fur-
ther supported by the significantly lower scores on the
global health status domains of the QLQ-C30 question-
naire after ALND compared with SLNB.
Scores on the breast symptoms domain of the
QLQ-BR23 indicated that symptoms were worse immedi-
ately after surgery in those undergoing mastectomy, but by
6months patients in the BCS groups had more symptoms
overall, which may be due to the addition of radiotherapy
in this period. Patients who underwent mastectomy also
had significantly lower QLQ-C30 global health status
scores at 6weeks than those who had BCS, although there
was no difference at 6months. As expected, body image
was worse in patients who had mastectomy than those who
underwent BCS. These differences were already present at
the baseline assessment, which could be a result of patients
anticipating the surgery, or may reflect that patients opting
for mastectomy already had lower body image scores
contributing to their decision. Further work is needed in
this area. It is worth noting that some of the differences in
mean scores were small when taken in context of the 0–100
scale, so may be of little clinical or practical importance.
For example, for EORTC QLQ-C30 global health status,
it has been suggested that a difference of 8 points or more
is important39.
Breast and axillary surgery are low risk in selected patients
in the elderly breast cancer population, although not with-
out complications or impact on QoL, and this should be
taken into account. Age remains an independent predictor
of the type of treatment an older women with breast cancer
receives.
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